In Brief: GDUFA inspections, FDA’s inspection workforce, device warning letters, 3D drug printers, CMC/GMP guidance agenda
This article was originally published in The Gold Sheet
Executive Summary
FDA discusses GDUFA II inspectional transparency issues with industry; FDA plans global workforce; device warning letter rate fell; why FDA needs a 3D drug printer; and CMC trumps GMP in FDA agenda.
You may also be interested in...
GDUFA II: Inspection Information Takes Center Stage
Sponsors say transparency is important as generic drug user fee negotiations move to inspection policy.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.